Hormone‐substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active‐controlled DURATION‐8 study

Aim To determine the effects of individual and combined therapies on plasma insulin, glucagon, β‐hydroxybutyrate (β‐OH) and associated metabolites. Materials and Methods In DURATION‐8, the combination of once‐weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin‐reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb. The study...